| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| melanoma vaccine (alvac) | cancer/testis antigen 1 | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] |
NA | discontinued in phase 2 | unknown |
| melanoma vaccine (alvac) | melanoma-associated antigen 1 | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] |
NA | discontinued in phase 2 | unknown |
| melanoma vaccine (alvac) | melanoma-associated antigen 3 | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] |
NA | discontinued in phase 2 | unknown |
| melanoma vaccine (alvac) | mart-1 melanoma antigen | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] |
NA | discontinued in phase 2 | unknown |
| melanoma vaccine (alvac) | melanocytes lineage-specific antigen gp100 | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] |
NA | discontinued in phase 2 | unknown |
| click here to return to the previous page | ||||||||